Biomarkers of therapeutic responsiveness

Abstract

The present invention relates to methods of diagnosing a kidney disorder in a patient, as well as methods of monitoring the progression of a kidney disorder and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein.

1 .- 39 . (canceled) 
     
     
         40 . A method of administering a treatment regimen to a patient in need thereof for treating melanoma, wherein said treatment regimen is sorafenib, said method comprising:
 (a) measuring a baseline level of at least one biomarker in a test sample obtained from said patient before undergoing said treatment regimen, wherein the at least one biomarker is VEGF and measuring an interim level of the at least one biomarker in a test sample obtained from the patient after undergoing said treatment regimen;   (b) comparing said baseline level of said at least one biomarker to the interim level of said at least one biomarker;   (c) continuing administration of said treatment regimen to said patient when in step (b) said interim level of VEGF is higher than the baseline level; and   (d) modifying administration of said treatment regimen to said patient if in step (b) said interim level of VEGF is lower than the baseline level.   
     
     
         41 . The method according to  claim 40 , wherein said at least one biomarker is a plurality of biomarkers including VEGF, and wherein said measuring step comprises conducting a multiplexed assay measurement of said plurality of biomarkers in said test sample, wherein said multiplexed assay measurement is conducted using one reaction volume comprising said test sample. 
     
     
         42 . The method of  claim 40 , wherein said method comprises measuring levels of two or more biomarkers. 
     
     
         43 . The method of  claim 42 , wherein said levels of two or more markers comprise phospohr-Rb. 
     
     
         44 . The method of  claim 40 , wherein said treatment regimen comprises administering an agonist of a VEGF-signaling pathway. 
     
     
         45 . The method of  claim 40 , which comprises an immunoassay. 
     
     
         46 . The method of  claim 45 , which is conducted in a multi-well assay plate. 
     
     
         47 . The method of  claim 45 , which is conducted in a cartridge. 
     
     
         48 . The method of  claim 45 , wherein the multi-well assay plate comprises a plurality of electrodes. 
     
     
         49 . The method of  claim 46 , wherein the cartridge comprises a plurality of electrodes. 
     
     
         50 . The method of  claim 45 , wherein the immunoassay comprises a support comprising a binding reagent immobilized thereto, wherein said first binding reagent binds at least one of said biomarkers, wherein said support is a particle. 
     
     
         51 . The method of  claim 45 , wherein the immunoassay further comprises a detectable label to measure the level of said biomarker. 
     
     
         52 . The method of  claim 51 , wherein the detectable label is measured by a measurement of light scattering, optical absorbance, fluorescence, chemiluminescence, electrochemiluminescence, bioluminescence, phosphorescence, radioactivity, magnetic field, or combinations thereof. 
     
     
         53 . The method of  claim 51 , wherein the detectable label is an ECL label and the measuring step comprises measuring an ECL signal.